Vericel Co. (NASDAQ:VCEL) Director Sells $156,250.00 in Stock

Vericel Co. (NASDAQ:VCEL) Director Robert L. Md Zerbe sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total transaction of $156,250.00. Following the transaction, the director now owns 26,595 shares of the company’s stock, valued at approximately $1,662,187.50. This represents a 8.59 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Vericel Trading Down 2.3 %

VCEL opened at $58.35 on Monday. Vericel Co. has a 1-year low of $39.12 and a 1-year high of $63.00. The stock has a market capitalization of $2.88 billion, a PE ratio of 972.66 and a beta of 1.72. The firm has a 50-day moving average price of $57.84 and a two-hundred day moving average price of $51.15.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. Vericel had a net margin of 1.56% and a return on equity of 1.48%. The business had revenue of $57.91 million during the quarter, compared to analyst estimates of $55.32 million. On average, research analysts predict that Vericel Co. will post 0.14 EPS for the current year.

Analyst Ratings Changes

VCEL has been the subject of several analyst reports. Stephens restated an “overweight” rating and set a $65.00 target price on shares of Vericel in a research report on Wednesday, January 15th. Truist Financial lifted their price objective on Vericel from $61.00 to $67.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Vericel in a report on Wednesday, January 15th. BTIG Research lifted their price target on shares of Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Finally, StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research report on Tuesday, December 24th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Vericel has an average rating of “Moderate Buy” and a consensus price target of $63.14.

Institutional Investors Weigh In On Vericel

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Atria Investments Inc boosted its holdings in Vericel by 2.4% in the fourth quarter. Atria Investments Inc now owns 7,952 shares of the biotechnology company’s stock valued at $437,000 after acquiring an additional 184 shares during the last quarter. Louisiana State Employees Retirement System lifted its position in Vericel by 0.8% during the 4th quarter. Louisiana State Employees Retirement System now owns 23,900 shares of the biotechnology company’s stock valued at $1,312,000 after purchasing an additional 200 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Vericel by 22.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 322 shares during the last quarter. Farther Finance Advisors LLC grew its position in shares of Vericel by 48.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock worth $53,000 after buying an additional 405 shares during the period. Finally, Linden Thomas Advisory Services LLC raised its stake in shares of Vericel by 1.1% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 43,781 shares of the biotechnology company’s stock worth $2,404,000 after buying an additional 489 shares during the last quarter.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.